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Abstract To identify interacting proteins of survival motor
neuron (SMN) in neurons, a fetal human brain cDNA library
was screened using the yeast two-hybrid system. One identified
group of SMN interacting clones encoded the DNA transacti-
vator FUSE binding protein (FBP). FBP overexpressed in
HEK293 cells or endogenously expressed in fetal and adult
mouse brain bound specifically in vitro to recombinant SMN
protein. Furthermore, an anti-FBP antibody specifically co-
immunoprecipitated SMN when both proteins were overex-
pressed in HEK293 cells. These results demonstrate that FBP is
a novel interacting partner of SMN and suggests a possible role
for SMN in neuronal gene expression.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive
disease that is the second most common genetic cause of
childhood death [1,2]. The pathological hallmark of SMA is
the degeneration of the anterior motor neurons in the spinal
cord [3]. SMA is classi¢ed into three subtypes (type I or
Werdnig^Ho¡man disease, type II, and type III or Kugel-
berg^Welander disease) based on the age of onset and severity
of the disease [4]. All three subtypes of SMA map to chromo-
some 5q11.2^13.3 [5,6] and the determining gene has been
identi¢ed as the survival motor neuron (SMN) gene [7].
The SMN gene encodes a putative 294 amino acid protein
[7] that shares no sequence homology with any known pro-
tein. The SMN protein is expressed fairly ubiquitously in a
variety of tissues [7,8]. In SMA patients compared to control
patients, the relative expression level of the SMN protein is
reduced signi¢cantly in the spinal cord and liver [8,9] and
modestly in ¢broblasts, lymphocytes, and skeletal muscle [8],
which makes it intriguing why alterations in SMN expression
primarily and speci¢cally a¡ect the function of motor neurons
in the spinal cord. We have shown that the SMN protein is
di¡erentially localized in spinal cord and skeletal muscle [10],
two of the target tissues of SMA, which suggests that the
speci¢city of SMN could be due to its association with tissue
speci¢c factors or imply tissue speci¢c functions.
Currently, there are several functions proposed for SMN
including a role in RNA processing [11^13], a role in anti-
apoptotic e¡ects [14], and a role in regulating gene expression
[15]. However, these studies were performed in various cell
types (Xenopus oocytes, HeLa, or NT-2) and not in the pri-
mary SMA target tissue, the neuron. To date, the only re-
ported study using spinal cord motor neurons suggests that
SMN’s role in RNA processing is conserved in this tissue [16].
In addition, ultrastructural studies of the spinal cord anterior
horn suggest that the SMN protein may have neuronal spe-
ci¢c functions in nucleocytoplasmic and dendritic transport
[16].
Both SMN mRNA and protein have been detected in fetal
tissue [17,18]. Since early embryonic SMN de¢cient mice
undergo massive cell death [19], SMN must play a critical
role in development. Determination of SMN’s role and iden-
tifying the proteins with which it interacts in developing neu-
rons should help to reveal the mechanism by which mutations
in SMN lead speci¢cally to the loss of motor neurons. To
approach this problem, we used SMN as a bait to screen a
fetal human brain library in the yeast two-hybrid interaction
trap system and have identi¢ed the FUSE binding protein
(FBP) as a novel interacting partner of SMN.
2. Materials and methods
2.1. Materials
The Saccharomyces cerevisiae EGY48 strain, the human fetal brain
acid fusion cDNA library, and the plasmids pEG202, pSH18-34,
pJK101, pSH17-4, and pRFHM1 [20] were generously provided by
Dr. R. Brent (Massachusetts General Hospital, Boston, MA). The
FBP expression plasmid, pcDNA1.1-FBP, and anti-FBP antibody
were generously provided by Dr. D. Levens (NIH, Bethesda, MD).
2.2. Yeast two-hybrid interaction trap screening
The manipulation of yeast and the screening of the fetal brain
interaction trap cDNA library were performed according to Finley
and Brent [21]. Brie£y, the SMN cDNA encoding amino acids 1^
294 [10] was cloned into pEG202. The resulting bait plasmid,
pEG202-SMN, and plasmids of the human fetal brain acid fusion
cDNA library were cotransformed into the EGY48 yeast strain. The
transformants (V1.2U106) were tested for galactose dependent
growth on Leu3 medium and for galactose dependent L-galactosidase
activity, resulting in 103 positive clones. Plasmid miniprep DNA from
each positive yeast clone was isolated and the cDNA inserts were
categorized into 16 groups by restriction enzyme analysis [21]. Sub-
sequently, library plasmids from each group were rescued [21] by
transforming KC8 Escherichia coli (Clontech, Inc., Palo Alto, CA).
The interaction with SMN in the EGY48 yeast strain was veri¢ed as
previously described [21].
2.3. DNA sequencing
The pEG202-SMN bait plasmid and the library plasmid inserts
were sequenced as previously described [10].
2.4. Construction of the SMN expression plasmid
To express SMN in cultured mammalian cells, we created a plasmid
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containing a hemagglutinin (HA) SMN chimera by replacing the
Rab3 coding region of the pCI-HA-Rab3 plasmid (generously pro-
vided by Dr. B. Dickey, Baylor College of Medicine) with the coding
region of the SMN cDNA. The resulting plasmid, pCI-HA-SMN,
encodes the V46 kDa HA tagged SMN protein.
2.5. Transient transfection of HEK293 cells and preparation of cell
lysates
Monolayer cultures of HEK293 cells (V3U106 per 100 mm plate)
were transfected with the indicated expression plasmids using the
TransFast reagent (Promega, Madison, WI). Forty-eight hours after
transfection, the cells were scraped into lysis bu¡er (50 mM Tris, pH
7.5, 2 mM EGTA, 0.1% NP-40, 2 mM aminobenzamidine, 1 mM
phenylmethylsulfonyl £uoride, and 10 Wg/ml each of aprotinin, leu-
peptin, and pepstatin). After brief sonication, the cell lysates were
clari¢ed by centrifugation at 15 000Ug for 15 min at 4‡C.
2.6. Preparation of brain lysates
At the time they were killed, the whole brains from adult and fetal
(E18.5 day) mice were removed and then immediately placed into
liquid nitrogen. The frozen brains were weighed, minced, and resus-
pended in 10 volumes (w/v) of lysis bu¡er. After homogenization and
brief sonication, the brain lysates were clari¢ed by centrifugation at
15 000Ug for 15 min at 4‡C.
2.7. In vitro protein binding assay
Bacterially expressed, puri¢ed E. coli maltose binding protein
(MBP) and MBP^SMN fusion protein [10] were prebound to amylose
beads (New England Biolabs, Beverly, MA) for 1 h at 4‡C in TE
bu¡er (50 mM Tris, pH 7.5, 2 mM EGTA). Lysates from cells trans-
fected with pcDNA1.1-FBP (V100 Wg/450 Wl) or from brain tissue
(V2 mg/450 Wl) were incubated with MBP or MBP^SMN beads over-
night at 4‡C. After extensive washing, the bound proteins were solu-
bilized in 2ULaemmli SDS sample bu¡er [22] and separated on a 12%
SDS^polyacrylamide gel. The separated proteins were analyzed by
Western blot [10] using a 1:1000 dilution of rabbit polyclonal anti-
FBP antibody and detected by chemiluminescence using the Super-
Signal0 substrate (Pierce, Rockford, IL).
2.8. Co-immunoprecipitation assay
Lysates prepared from HEK293 cells transiently transfected with
the control vector pCI-HA-Rab3 (containing an unrelated cDNA),
pCI-HA-SMN, and/or pcDNA1.1-FBP were precleared by incubation
with a 1:500 dilution of normal rabbit IgG for 1 h at 4‡C, followed by
precipitation with UltraLink1 Immobilized Protein A/G Plus (Pierce,
Rockford, IL). The precleared samples were incubated with a 1:500
dilution of the anti-FBP antibody for 2 h at 4‡C and then precipitated
with Protein A/G Plus. The immunoprecipitates were separated on a
12% SDS^polyacrylamide gel as described above and immunoblotted
using a 1:1000 dilution of the mouse monoclonal anti-HA antibody
(clone 12CA5, Boehringer Mannheim, Indianapolis, IN) to detect the
SMN protein.
3. Results
3.1. Identi¢cation of SMN interacting cDNA clones
We screened a human fetal brain cDNA library by the yeast
two-hybrid interaction trap method using SMN as the bait,
which resulted in 103 positive clones. These positive clones
were classi¢ed into 16 groups based on restriction enzyme
analysis and partial DNA sequencing. One of these groups
consisted of 40 independent partial cDNA clones with a
V1.6 kb insert. BLAST search of GenBank revealed that
this insert encoded amino acid residues 7^280 of the previ-
ously identi¢ed SMN interacting protein 1 or SIP1 [12]. A
second group consisted of 27 independent partial cDNA
clones with an insert size of 0.8 or 1.2 kb. This second group
of cDNA clones contained an open reading frame encoding
the FBP [23] with the 0.8 kb insert encoding amino acids
571^644 and the 1.2 kb insert encoding amino acids 521^
644. Since the number of independent clones in each of the
other 14 groups was signi¢cantly lower, we have not fully
characterized these putative SMN interacting clones.
To quantify the interactions with SMN, the EGY48 yeast
strain was co-transformed with the SMN bait plasmid and
one of the library plasmids containing the partial SIP1 or
FBP cDNA. In two independent assays, galactose induced
L-galactosidase activity in each transformant was quanti¢ed
using ONPG as the substrate (Table 1). In the presence of
glucose, the L-galactosidase levels in the yeast cotransformed
with the SMN bait and a library plasmid were similar to those
found in the yeast transfected with the negative control plas-
mid alone. However, in the presence of galactose, yeast co-
transformed with the plasmids containing the SMN bait and
the SIP1 or FBP partial cDNA displayed high levels of L-
galactosidase activity. Additionally, interaction of the ex-
pressed SMN bait with the longer fragment of FBP (amino
acids 521^644) resulted in V7.9-fold higher L-galactosidase
activity than the shorter fragment of FBP (amino acids 571^
644). The L-galactosidase activity resulting from SMN’s inter-
action with the longer FBP fragment was quantitatively sim-
ilar to that resulting from SMN’s interaction with SIP1. These
results suggest that in the yeast two-hybrid system, interaction
Fig. 1. SMN interacts with FBP in vitro. Cell or tissue lysates were
subjected to an in vitro protein binding assay using MBP or MBP^
SMN immobilized to amylose beads and then Western blotted with
anti-FBP antibody as described in Section 2. A: Western blot of ly-
sates from HEK293 cells transiently transfected with control vector
(C) or pcDNA1.1-FBP plasmid (F). B: Western blot of tissue ly-
sates from fetal (F) or adult (A) mouse brain.
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of SMN with the FBP is as strong as its interaction with the
previously characterized SIP1 protein.
3.2. Interaction of SMN with FBP in vitro and in vivo
To verify the yeast two-hybrid results, we tested whether
FBP could bind to SMN in vitro. Puri¢ed MBP or MBP^
SMN bound to amylose beads was separately incubated
with HEK293 cell lysates or brain tissue lysates. The bound
proteins were resolved by SDS^PAGE and FBP was detected
by Western blot analysis. Fig. 1 shows the results of one
representative experiment (n = 4). As shown in Fig. 1A, the
recombinant full-length FBP is expressed as a V74 kDa pro-
tein in HEK293 cell lysates and is captured from the lysate by
the MBP^SMN fusion protein bound beads, but not by the
MBP protein bound beads. Similar results were obtained with
the endogenously expressed FBP in fetal and adult mouse
brain extracts (Fig. 1B). These results indicate that SMN
and FBP interact in vitro.
To demonstrate that SMN and FBP interact in vivo, we
performed co-immunoprecipitation experiments (n = 4).
HEK293 cells were transiently transfected with pCI-HA-
Rab3 (control plasmid), pCI-HA-SMN (HA-SMN expression
plasmid), and both pCI-HA-SMN and pcDNA1.1-FBP (FBP
expression plasmid). An anti-FBP antibody was used for im-
munoprecipitation from cell lysates prepared from each trans-
fected plate. The immunoprecipitates were analyzed by immu-
noblotting with the 12CA5 monoclonal antibody. The HA-
SMN protein was detected as a V46 kDa protein in the
cell lysate prepared from cells transfected with the SMN ex-
pression plasmid (Fig. 2A,B). After immunoprecipitation with
the anti-FBP antibody, the HA-SMN protein was detected in
the lysate of cells overexpressing both HA-SMN and FBP
(Fig. 2A,B), but neither in the control lysate (Fig. 2A) nor
in the cell lysate expressing HA-SMN alone (Fig. 2B). The
prominent band detected in the control lysate at V32 kDa is
the HA tagged Rab3 protein. Similar size but less intense non-
speci¢c bands also appear in the other lanes. Taken together,
these results indicate that SMN interacts with FBP in vivo.
4. Discussion
Previously, SMN was shown to interact with the RNA
binding protein ¢brillarin [11], a novel protein named SIP1
[12], an anti-apoptotic protein Bcl-2 [14], and the nuclear tran-
scription activator E2 of papillomavirus [15]. Additionally,
SMN was demonstrated to interact with itself [11,14]. These
SMN interacting proteins were identi¢ed either from a HeLa
cell cDNA library [11,12,15] or from a human thymocyte
cDNA library [14], suggesting that SMN could play a univer-
sal role in all cells. However, none of these interactions pro-
vide any clue as to the relationship between an SMN gene
defect and speci¢cally, degeneration of motor neurons. Using
the yeast two-hybrid interaction trap system, we isolated FBP
as an SMN interacting protein from a fetal brain library. The
SMN^FBP interaction was biochemically veri¢ed by in vitro
binding of SMN fusion protein to the full-length recombinant
FBP expressed in cultured mammalian cells and to the endo-
genously expressed FBP in fetal and adult mouse brain. Fur-
thermore, the in vivo interaction between SMN and FBP was
con¢rmed by a co-immunoprecipitation assay. Collectively,
the results obtained from the yeast two-hybrid system, in vitro
protein binding assay, and co-immunoprecipitation assay
strongly supports an in vivo interaction of FBP and SMN.
FBP was originally cloned by Duncan et al. [23] and be-
longs to a family of single stranded DNA binding transacti-
vators [24]. FBP contains two functional domains: a DNA
binding domain and a transactivating domain [23,24]. The
DNA binding domain is located in the central part of FBP
Table 1
Veri¢cation of SMN interactions
Expressed proteins L-Galactosidase activity (AU)
glucose galactose
Lex A/Gal4 fusion protein
(positive control)
7935 þ 347 ND
LexA/biconoid fusion protein
(negative control)
9 þ 3 ND
SMN+SIP1 (amino acids 7^280) 5 þ 1 1030 þ 88
SMN+FBP (amino acids 521^644) 5 þ 2 912 þ 17
SMN+FBP (amino acids 571^644) 5 þ 1 116 þ 2
EGY48 yeast were transformed with control plasmids or with the
SMN bait plasmid and a library plasmid encoding the indicated
proteins. The library cDNA inserts are under the control of the
GAL1 promoter. The control proteins are under the control of the
constitutive ADH promoter. Three independent colonies from each
yeast transformation were grown overnight at 30‡C in synthetic me-
dium containing either glucose or galactose and then assayed for
L-galactosidase activity using o-nitrophenyl-L-D-galactoside as the
substrate [21]. L-Galactosidase activity is expressed in arbitrary
units, AU (mean þ S.E.M.). ND = not determined.
Fig. 2. SMN interacts with FBP in vivo. Cell lysates were prepared
from transiently transfected HEK293 cells. The anti-FBP antibody
was used for immunoprecipitation (FBP IP) and the anti-HA tag
antibody was used for Western blotting as described in Section 2.
A: Western blot of lysates and immunoprecipitates from HEK293
cells transfected with control plasmid (C) or with both pcDNA1.1-
FBP and pCI-HA-SMN plasmids (F+S). B: Western blot of lysates
and immunoprecipitates from HEK293 cells transfected with pCI-
HA-SMN plasmid (S) or with both pcDNA1.1-FBP and pCI-HA-
SMN plasmids (F+S).
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and is comprised of four ‘FBP repeat’ sequences [23]. The
‘FBP repeat’ has high homology with the RNA binding KH
domain of hnRNP protein K [25]. The transactivating domain
of FBP is located in the C-terminus and contains three tyro-
sine motifs with the conserved sequence of AW(A/E)(A/E)YY
at amino acids 531^547, 584^592, and 609^626 [26]. Interest-
ingly, all the partial cDNA clones of FBP that interacted with
the SMN bait in the yeast two-hybrid system encoded at least
the last two tyrosine motifs. The FBP clone that elicited the
highest L-galactosidase activity when cotransfected with the
SMN bait in the yeast EGY48 encodes all three tyrosine mo-
tifs. These results suggest that SMN binds within the trans-
activating domain of FBP and the a⁄nity of this interaction is
dependent on the presence of the tyrosine motifs.
Two functions for FBP have been identi¢ed: one as a tran-
scriptional regulator of the growth promoting c-myc gene [23]
and the second as an mRNA stability regulator of GAP-43
[27], which plays a key role in axonal growth and in the
formation of neural connections [28]. FBP is expressed only
in proliferating and undi¡erentiated cells and not in quiescent,
di¡erentiated cells [23,29]. FBP expression is also developmen-
tally regulated [30]. The highest levels of FBP mRNA and
protein were detected in both the mouse and chicken embry-
onic brain [30]. In adult, however, the FBP protein was de-
tected only in the brain and testis [30]. Furthermore, the rel-
ative expression level of FBP protein was decreased in adult
mouse brain as compared to that in the embryonic brain [30].
In agreement with the lower expression of FBP in the adult
brain, we found relatively less SMN bound FBP in the extract
of adult mouse brain than in the extract of fetal mouse brain
(Fig. 1B).
The expression of SMN mRNA and protein is also devel-
opmentally regulated. The SMN mRNA was detected in neu-
ral tissue as early as 8 weeks of human fetal life and was
found to be present throughout postnatal and adult life,
which suggested that SMN might play a role in neuronal
development [17]. More speci¢cally, during the second fetal
trimester, SMN mRNA was detected in neuroblast cells and
expression in the motor neurons was maintained from neo-
natal to adulthood [17]. The SMN protein is expressed at 16
fetal weeks with relatively high expression levels detected in
the brain and the kidney [18]. In contrast, the relative expres-
sion level of SMN was signi¢cantly lower in most postnatal
tissues examined compared to their respective fetal tissues
[18]. Based on the expression pattern in various tissues exam-
ined so far, the developmental expression pattern of the SMN
protein in brain seems to parallel that of FBP. Since FBP and
SMN both are highly expressed in developing neuronal tissue,
it is conceivable that an interaction between the SMN and
FBP might be critical for motor neuron development and
that a disruption of this interaction might contribute to the
onset of the SMA disease (especially in type I, which begins in
utero and is the most severe).
In summary, we have demonstrated that the DNA trans-
activator FBP protein is a novel interacting partner of SMN.
Since this interaction with SMN was originally identi¢ed from
a human fetal brain library, this may have relevance to SMN’s
speci¢c role in the neuron.
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